Skip to main content
Premium Trial:

Request an Annual Quote

Exagen Diagnostics Raises $5.4M in Series A Financing

NEW YORK, Jan. 14 (GenomeWeb News) - Exagen Diagnostics has raised more than $5.4 million in a series A financing round, the company said today. Lead investor Tullis-Dickerson was joined by vSpring Capital and Wasatch Venture Fund.

 

Exagen, based in Albuquerque, N.M., uses computational methods to develop genomic markers. It is currently validating prognostic marker sets for breast cancer and hepatitis C that aim to guide treatment decisions.

 

The company was founded in 2002 as a spinoff from Quasar International. It has adapted a computational method used by Quasar to find defects in automotive parts to analyze large amounts of genomic data. Exagen plans to license its genomic marker sets to large diagnostic laboratories.

 

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.